Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study.


Journal

Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 27 12 2018
revised: 19 02 2019
accepted: 06 03 2019
pubmed: 16 3 2019
medline: 21 4 2020
entrez: 16 3 2019
Statut: ppublish

Résumé

Clostridioides (Clostridium) difficile is the leading cause of healthcare-associated infectious diarrhea in the developed world. Retrospective studies have shown a lower incidence of C. difficile infection (CDI) in Japan than in Europe or North America. Prospective studies are needed to determine if this is due lack of testing for C. difficile or a true difference in CDI epidemiology. A prospective cohort study of CDI was conducted from May 2014 to May 2015 at 12 medical facilities (20 wards) in Japan. Patients with at least three diarrheal bowel movements (Bristol stool grade 6-7) in the preceding 24 h were enrolled. CDI was defined by positive result on enzyme immunoassay for toxins A/B, nucleic acid amplification test for the toxin B gene or toxigenic culture. C. difficile isolates were subjected to PCR-ribotyping (RT), slpA-sequence typing (slpA-ST), and antimicrobial susceptibility testing. The overall incidence of CDI was 7.4/10,000 patient-days (PD). The incidence was highest in the five ICU wards (22.2 CDI/10,000 PD; range: 13.9-75.5/10,000 PD). The testing frequency and CDI incidence rate were highly correlated (R

Identifiants

pubmed: 30872073
pii: S1075-9964(19)30046-0
doi: 10.1016/j.anaerobe.2019.03.007
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

102011

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Haru Kato (H)

Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan. Electronic address: cato@nih.go.jp.

Mitsutoshi Senoh (M)

Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.

Hitoshi Honda (H)

Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

Tadashi Fukuda (T)

Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.

Yasuaki Tagashira (Y)

Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

Hiroko Horiuchi (H)

Hachinohe City Hospital, Aomori, Japan.

Hiroshi Chiba (H)

Hachinohe City Hospital, Aomori, Japan.

Daisuke Suzuki (D)

Kameda Medical Center, Chiba, Japan.

Naoto Hosokawa (N)

Kameda Medical Center, Chiba, Japan.

Hidetaka Kitazono (H)

Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.

Yasuhiro Norisue (Y)

Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.

Hisashi Kume (H)

Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.

Nobuaki Mori (N)

National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Hideo Morikawa (H)

National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Saeko Kashiwagura (S)

National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Akiko Higuchi (A)

National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Hideaki Kato (H)

Toyokawa City Hospital, Aichi, Japan.

Makoto Nakamura (M)

Toyokawa City Hospital, Aichi, Japan.

Saori Ishiguro (S)

Toyokawa City Hospital, Aichi, Japan.

Sayuri Morita (S)

Toyokawa City Hospital, Aichi, Japan.

Hideaki Ishikawa (H)

Tokai Central Hospital, Gifu, Japan.

Takuya Watanabe (T)

Tokai Central Hospital, Gifu, Japan.

Katsuyuki Kojima (K)

Tokai Central Hospital, Gifu, Japan.

Izumi Yokomaku (I)

Tokai Central Hospital, Gifu, Japan.

Tatsuya Bando (T)

Tokai Central Hospital, Gifu, Japan.

Kayoko Toimoto (K)

Nara Medical University, Nara, Japan.

Kei Moriya (K)

Nara Medical University, Nara, Japan.

Kei Kasahara (K)

Nara Medical University, Nara, Japan.

Seigo Kitada (S)

National Hospital Organization Toneyama National Hospital, Osaka, Japan.

Junko Ogawa (J)

National Hospital Organization Toneyama National Hospital, Osaka, Japan.

Haruko Saito (H)

National Hospital Organization Toneyama National Hospital, Osaka, Japan.

Harumi Tominaga (H)

National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Yousuke Shimizu (Y)

National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Fumi Masumoto (F)

National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Kayoko Tadera (K)

National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Junichi Yoshida (J)

Shimonoseki City Hospital, Yamaguchi, Japan.

Tetsuya Kikuchi (T)

Shimonoseki City Hospital, Yamaguchi, Japan.

Ichiro Yoshikawa (I)

University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.

Tatsuyuki Watanabe (T)

University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.

Masahisa Honda (M)

University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.

Kuniko Yokote (K)

University Hospital, University of Occupational and Environmental Health, Fukuoka, Japan.

Takao Toyokawa (T)

Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.

Hiroko Miyazato (H)

Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.

Mika Nakama (M)

Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.

Cedric Mahe (C)

Sanofi Pasteur, Lyon, France.

Kimberly Reske (K)

Section of Transplant Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.

Margaret A Olsen (MA)

Section of Transplant Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.

Erik R Dubberke (ER)

Section of Transplant Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH